Last reviewed · How we verify
Placebo Narlaprevir
Narlaprevir is a protease inhibitor used to treat hepatitis C virus (HCV) infection.
Narlaprevir is a protease inhibitor used to treat hepatitis C virus (HCV) infection. Used for Chronic hepatitis C virus (HCV) infection, HCV genotype 1 infection.
At a glance
| Generic name | Placebo Narlaprevir |
|---|---|
| Sponsor | R-Pharm |
| Drug class | protease inhibitor |
| Target | NS3/4A protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
Narlaprevir works by inhibiting the NS3/4A protease enzyme, which is essential for the replication of the HCV virus. This leads to a reduction in viral load and an improvement in liver function. Narlaprevir is often used in combination with other antiviral medications to achieve optimal treatment outcomes.
Approved indications
- Chronic hepatitis C virus (HCV) infection
- HCV genotype 1 infection
Common side effects
- Fatigue
- Headache
- Nausea
- Diarrhea
- Abdominal pain
Key clinical trials
- Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study) (PHASE3)
- Safety, Tolerability, PK and PD of SCH 900518 in Naive or Treatment-Experienced Subjects Infected With HCV Genotype 1 (Protocol No. P04695) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo Narlaprevir CI brief — competitive landscape report
- Placebo Narlaprevir updates RSS · CI watch RSS
- R-Pharm portfolio CI